Remove Containment Remove Licensing Remove Marketing Remove Sales
article thumbnail

Gilead wins patent battle with US government over HIV PrEP drugs

Pharmaceutical Technology

According to the US government, Gilead had repeatedly refused to license patents related to PrEP research undertaken by the Department of Health and Human Services’ (HHS) Centers for Disease Control and Prevention (CDC). Gilead markets both Truvada and its successor Descovy.

article thumbnail

Adalvo signs licence deal with EQL Pharma for Mellozzan

Pharmaceutical Technology

Adalvo has entered a strategic licensing agreement with Swiss pharmaceutical company EQL Pharma for Mellozzan (melatonin) outside Europe and the US. Mellozzan contains the sleep hormone melatonin and is indicated for use in children with attention deficit hyperactivity disorder (ADHD) and sleep difficulties.

Hormones 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Soliton Appoints Sean J. Shapiro as Vice President of Sales

The Pharma Data

Shapiro as Vice President of Sales, effective January 1, 2021. Sean is a seasoned sales executive who has successfully launched several aesthetic devices in the industry, and we look forward to leveraging his extensive experience as we prepare for the commercial launch of our RAP technology during the first half of next year.”

Sales 52
article thumbnail

Bang Energy’s Twist of Fate: Monster Energy as Potential Buyer

XTalks

This transaction is pending approval from the bankruptcy court and the Federal Trade Commission (FTC), which is currently reviewing the potential sale; however, if given the green light, this deal could potentially be beneficial for both brands. That year, Red Bull led the market with $6.8 billion and Bang earning a respectable $1.3

article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

Ltd (“Juyou”), a biotechnology company that develops and sells medical and cosmetic skincare products, for the commercialization and development of Pliaglis ® in mainland China (the “License Agreement”). million and US$1.8 million and US$1.8 About Juyou Bio – Technology Co.

article thumbnail

Radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

The Pharma Data

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These targeted drugs bind to markers or proteins over-expressed by certain tumors, or tumor-associated tissue, such as stroma. Disclaimer. Source link:[link].

Protein 52
article thumbnail

Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan

The Pharma Data

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., The Otsuka group of companies employed 47,000 people worldwide and had consolidated sales of approximately USD 13 billion in 2019. VICTORIA, British Columbia & ROCKVILLE, Md.–(